Inflarx N.V. (IFRX) closed at $1.56 on October 23, 2026, up 2.0% from the previous close, on volume of 886,450 shares (30-day average 634,302).
Data as of October 23, 2026.
23-Oct-2026
TipRanks (Fri, 23-Oct 6:50 AM ET)
InflaRx Showcases Izicopan’s Renal Protection Data at Kidney Week 2026
TipRanks (Thu, 22-Oct 4:27 PM ET)
InflaRx Highlights Izicopan's Therapeutic Potential at Kidney Week 2026
Globe Newswire (Thu, 22-Oct 12:00 PM ET)
InflaRx to Present Late-Breaking Pre-clinical Data on Izicopan at Kidney Week 2026
Globe Newswire (Fri, 2-Oct 7:30 AM ET)
Globe Newswire (Thu, 1-Oct 7:30 AM ET)
InflaRx to Host Virtual Capital Markets Day
Globe Newswire (Mon, 21-Sep 7:30 AM ET)
InflaRx Announces Participation in September Investor Conferences
Globe Newswire (Thu, 20-Aug 7:30 AM ET)
InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones
Globe Newswire (Thu, 6-Aug 7:30 AM ET)
InflaRx to Report Second Quarter 2026 Results on August 6, 2026
Globe Newswire (Thu, 30-Jul 7:30 AM ET)
InflaRx Raises $150 Million in Major Offering Backed by Top Healthcare Investors
Market Chameleon (Wed, 6-May 5:55 AM ET)
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
Inflarx N.V. trades on the NASDAQ stock market under the symbol IFRX.
As of October 23, 2026, IFRX stock price climbed to $1.56 with 886,450 million shares trading.
IFRX has a beta of 3.46, meaning it tends to be more sensitive to market movements. IFRX has a correlation of 0.23 to the broad based SPY ETF.
IFRX has a market cap of $229.78 million. This is considered a Small Cap stock.
Last quarter Inflarx N.V. reported $0 in Revenue and -$.10 earnings per share. This fell short of revenue expectation by $-10,000 and missed earnings estimates by -$.02.
In the last 3 years, IFRX traded as high as $2.95 and as low as $.71.
The top ETF exchange traded funds that IFRX belongs to (by Net Assets): GWX, QQQS.
IFRX has outperformed the market in the last year with a return of +27.9%, while the SPY ETF gained +14.3%. However, in the most recent history, IFRX shares have underperformed the stock market with its stock returning -9.8% in the last 3 month period and -2.5% for the last 2 week period, while SPY has returned +3.2% and -2.4%, respectively.
IFRX support price is $1.44 and resistance is $1.62 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IFRX shares will trade within this expected range on the day.